Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Chemical dissection of the cell cycle: probes for cell biology and anti-cancer drug development.

Senese S, Lo YC, Huang D, Zangle TA, Gholkar AA, Robert L, Homet B, Ribas A, Summers MK, Teitell MA, Damoiseaux R, Torres JZ.

Cell Death Dis. 2014 Oct 16;5:e1462. doi: 10.1038/cddis.2014.420.

2.

Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes.

Robert L, Harview C, Emerson R, Wang X, Mok S, Homet B, Comin-Anduix B, Koya RC, Robins H, Tumeh PC, Ribas A.

Oncoimmunology. 2014 Jun 25;3:e29244. eCollection 2014.

3.

CTLA4 blockade broadens the peripheral T-cell receptor repertoire.

Robert L, Tsoi J, Wang X, Emerson R, Homet B, Chodon T, Mok S, Huang RR, Cochran AJ, Comin-Anduix B, Koya RC, Graeber TG, Robins H, Ribas A.

Clin Cancer Res. 2014 May 1;20(9):2424-32. doi: 10.1158/1078-0432.CCR-13-2648. Epub 2014 Feb 28. Erratum in: Clin Cancer Res. 2015 Jul 15;21(14):3359.

4.

New drug targets in metastatic melanoma.

Homet B, Ribas A.

J Pathol. 2014 Jan;232(2):134-41. doi: 10.1002/path.4259. Review.

PMID:
24027077
5.

Update on the diagnosis of cancer of unknown primary (CUP) origin.

Ariza A, Balañá C, Concha Á, Hitt R, Homet B, Matilla A, Alba E.

Clin Transl Oncol. 2011 Jul;13(7):434-41. doi: 10.1007/s12094-011-0679-9.

PMID:
21775269
6.

Diagnosis of unknown primary cancer based on molecular techniques may influence therapeutic approach and improve survival.

Homet B, Hitt R, Ghanem I, Cortés-Funes H.

Clin Transl Oncol. 2010 Aug;12(8):574-5. doi: 10.1007/s12094-010-0556-y.

PMID:
20709655

Supplemental Content

Support Center